• Featured Product
  • KD/KO验证

CoraLite® Plus 488-conjugated androgen receptor Recombinant antibody

androgen receptor Recombinant Antibody for IF/ICC
Cat No. CL488-81844

产品说明书

CloneNo. 4O18

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

IF/ICC

AR, androgen receptor,AR, NR3C4, DHTR, 4O18

缓冲液配方:  PBS and Azide
PBS and Azide
偶联物:  CoraLite® Plus 488
规格: 

-/ -


经过测试的应用

Positive IF/ICC detected inLNCaP cells
Positive FC (Intra) detected inLNCaP cells
Planning an IHC experiment? We recommend our IHCeasy AR Ready-To-Use IHC Kit. AR primary antibody included.
For other applications, we recommend the unconjugated version of this antibody, 81844-1-PBS

推荐稀释比

应用推荐稀释比
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
Flow Cytometry (FC) (INTRA)FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

CL488-81844 targets androgen receptor in IF/ICC applications and shows reactivity with human samples.

经测试应用 IF/ICC Application Description
经测试反应性 human
免疫原 androgen receptor fusion protein Ag17291 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Recombinant
产品类型 Antibody
全称 androgen receptor
别名 AR, androgen receptor,AR, NR3C4, DHTR, 4O18
计算分子量 914 aa, 99 kDa
观测分子量110-120 kD
GenBank蛋白编号BC132975
基因名称 AR
Gene ID (NCBI) 367
RRIDAB_3673057
偶联类型 CoraLite® Plus 488 Fluorescent Dye
最大激发/发射波长493 nm / 522 nm
形式 Liquid
纯化方式Protein A purification
UNIPROT IDP10275
储存缓冲液 PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3
储存条件Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

Androgen receptor (AR) is a steroid hormone receptor for androgenic hormones such as 17β-Hydroxy-3-oxo-4-androstene and DHT. AR plays a vital role in developing and maintaining male sex phenotypes as well as an additional role in regulating bone metabolism.

1. What is the molecular weight of AR? Are there any isoforms of AR?
The molecular weight of full-length androgen receptor (AR-B) is 110 kDa. An additional variant, AR-A, has an 87 kDa size and lacks the N-terminal 187 amino acids of AR-A (PMID: 8108393). Recently, more splice variants of AR have been discovered, raising protein products of around 80 kDa length (PMID: 19244107), as well as an AR45 variant of 45 kDa size (PMID: 15634333). AR splice variants differ in their cell line-specific expression (PMID: 24570075).

2. What is the subcellular localization of AR?
AR can be present in either or both of the cytoplasm and nucleus. In androgen-deprived cells, AR is found predominantly in the cytoplasm, while stimulation by androgens causes enrichment of androgen-bound AR in the nucleus. AR shuttles between the cytoplasm and nucleus and its phosphorylation state has an impact on subcellular localization (PMID: 16282370).

3. Is AR post-translationally modified?
Post-translational modifications of the AR include phosphorylation, acetylation, methylation, SUMOylation, and ubiquitination (PMID: 21820033). These modifications have an impact on receptor stability, activity, and can change the observed molecular weight of the AR.

4. How to study AR signaling in cell culture?
It is important to control levels of cell stimulation while also looking at AR signaling. Fetal bovine serum (FBS) that is typically used in cell culture contains low levels of 17β-Hydroxy-3-oxo-4-androstene that are enough to stimulate the growth of prostate cells (PMID: 19676093), including the LNCaP cell line that is a commonly used human prostatic carcinoma cell model (PMID: 6831420). One possibility for complete 17β-Hydroxy-3-oxo-4-androstene deprivation is to use charcoal stripped FBS that removes lipophilic agents, including androgens. It is also not recommended to use phenol red in your medium because it is a weak estrogen (PMID: 3458212). Cell stimulation is often conducted by DHT.

5. What is the role of AR in prostate cancer?
AR plays a key role in the development and physiology of the prostate gland, and also cancer progression (PMID: 15082523). Mutations in AR altering ligands have been observed. The progression of the prostate cancer depends on AR activity and therefore blocking AR activity or lowering androgen levels is a key step related to androgen deprivation therapy (ADT).

实验方案

Product Specific Protocols
IF protocol for CL Plus 488 androgen receptor antibody CL488-81844Download protocol
FC protocol for CL Plus 488 androgen receptor antibody CL488-81844Download protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...